NCT00944229 - The Effect of Omega-3 Polyunsaturated Fatty Acids in Congestive Heart Failure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Heart Failure

Interventions

DRUG

LOVAZA (Omega-3)

LOVAZA 4 gm q24 for 8 weeks Each 1-gram capsule of LOVAZA (omega-3-acid ethyl esters) contains at least 900 mg of the ethyl esters of omega-3 fatty acids. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg).

DRUG

Placebo

4 capsules of placebo every 24 hours

Trial Locations (1)

10032

Columbia University Medical Center, New York